Acquiring Company
Merck
Acquired Company
EyeBio
RahwayManufacturingBiotechnologyHealthcareHealth CareBiotechnologyHealth CareMedicalTherapeuticsDescription
Merck has completed the acquisition of EyeBio, which further diversifies its late-stage pipeline with the addition of a promising candidate Restoret for the treatment of certain retinal diseases. This acquisition strengthens Merck's position in addressing unmet medical needs in patients with retinal diseases.
Quick answer
Merck is acquiring EyeBio, announced July 12, 2024. Merck is based in Rahway, New Jersey, United States.
- How much did Merck pay for EyeBio?
- The deal value was not disclosed.
- What does Merck do?
- For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our..
- Where are Merck and EyeBio based?
- Merck is based in Rahway, New Jersey, United States.
- Who are the decision-makers at Merck?
- Fundz holds 3 contacts at Merck. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- AA Medical completes acquisition of Surgical Product Solutions, forming strategic partnership (July 11, 2024)
- Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (August 9, 2024)
- BD acquires Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to enhance smart connected care solutions, $4.2B (June 3, 2024)
- KARL STORZ completes acquisition of Asensus Surgical, Inc. to strengthen its position in robotic and digital surgical market (August 22, 2024)
- Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (August 16, 2024)
Who to call at Merck, and when
When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Merck raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Merck, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired EyeBio?
EyeBio was acquired by Merck, based in Rahway. The deal was reported on July 12, 2024. Merck is publicly traded (MRK) and operates in Manufacturing.
When did Merck acquire EyeBio?
Merck's acquisition of EyeBio was reported on July 12, 2024. Merck has completed the acquisition of EyeBio, which further diversifies its late-stage pipeline with the addition of a promising candidate Restoret for the treatment of certain retinal diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does EyeBio do?
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.